Silicate, Borosilicate, and Borate Bioactive Glass Scaffolds with Controllable Degradation Rate for Bone Tissue Engineering Applications II
In vitro and in vivo biological evaluation
Anderson, James M.
In Part I, the in vitro degradation of bioactivAR52115e glass scaffolds with a microstructure similar to that of human trabecular bone, but with three different compositions, was investigated as a function of immersion time in a simulated body fluid. the glasses consisted of a silicate (13-93) composition, a borosilicate composition (designated 13-93B1), and a borate composition (13-93B3), in which one-third or all of the SiO2 content of 13-93 was replaced by B2O3, respectively. This work is an extension of Part I, to investigate the effect of the glass composition on the in vitro response of osteogenic MLO-A5 cells to these scaffolds, and on the ability of the scaffolds to support tissue infiltration in a rat subcutaneous implantation model. the results of assays for cell viability and alkaline phosphatase activity showed that the slower degrading silicate 13-93 and borosilicate 13-93B1 scaffolds were far better than the borate 13-93B3 scaffolds in supporting cell proliferation and function. However, all three groups of scaffolds showed the ability to support tissue infiltration in vivo after implantation for 6 weeks. the results indicate that the required bioactivity and degradation rate may be achieved by substituting an appropriate amount of SiO2 in 13-93 glass with B2O3, and that these trabecular glass scaffolds could serve as substrates for the repair and regeneration of contained bone defects.
Q. Fu et al., "Silicate, Borosilicate, and Borate Bioactive Glass Scaffolds with Controllable Degradation Rate for Bone Tissue Engineering Applications II," Journal of Biomedical Materials Research Part A, Wiley-Blackwell, Jan 2010.
The definitive version is available at https://doi.org/10.1002/jbm.a.32823
Materials Science and Engineering
International Standard Serial Number (ISSN)
Article - Journal
© 2010 Wiley-Blackwell, All rights reserved.